Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Study results from University of Miami in the area of cancer gene therapy published
June 24th, 2008
According to recent research published in the journal Cancer Gene Therapy, "Despite adequately expressing tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) receptors DR4/ DR5, malignant cells are frequently refractory to the cytotoxic effect of this apoptosis-inducing ligand. The susceptibility of cancer cells to TRAIL can be potentiated by cisplatin ( CDDP)." "This study was designed to evaluate the ability of cisplatin to enhance the cytotoxic effect of TRAIL gene therapy using the recombinant adenovirus-mediated tumor-selective expression of membrane-bound green fluorescence protein ( GFP)-TRAIL fusion protein ( AdVgTRAIL) on thoracic cancer...
Source: Cancer Weekly (2008-06-24)
|
